<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Candida infections of the abdomen and thorax</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Candida infections of the abdomen and thorax</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Candida infections of the abdomen and thorax</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carol A Kauffman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John W Baddley, MD, MSPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The clinical manifestations of infection with <em>Candida</em> species range from local mucous membrane infections to widespread dissemination with multisystem organ failure. Although <em>Candida</em> are considered normal microbiota in the gastrointestinal and genitourinary tracts of humans, they have the propensity to invade and cause disease when an imbalance is created in the ecological niche in which these organisms usually exist.</p><p>The immune response of the host is an important determinant of the type of infection caused by <em>Candida</em>. The different <em>Candida</em> species generally can cause all of the clinical syndromes, although infection with <em>Candida albicans</em> is the most common. The major importance of identifying the infecting organism is that some species are more resistant to azole antifungal agents than others. (See  <a class="medical medical_review" href="/d/html/2430.html" rel="external">"Management of candidemia and invasive candidiasis in adults"</a>.)</p><p>This topic will review the manifestations of <em>Candida</em> infection involving the abdomen and thorax. <em>Candida</em> peritonitis can complicate continuous peritoneal dialysis in patients with end-stage kidney disease, as discussed separately (see  <a class="medical medical_review" href="/d/html/1982.html" rel="external">"Fungal peritonitis in peritoneal dialysis"</a>). Other manifestations of <em>Candida </em>infections are discussed separately. (See  <a class="medical medical_review" href="/d/html/2416.html" rel="external">"Overview of Candida infections"</a> and  <a class="medical medical_review" href="/d/html/2462.html" rel="external">"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults"</a> and  <a class="medical medical_review" href="/d/html/2425.html" rel="external">"Chronic disseminated candidiasis (hepatosplenic candidiasis)"</a> and  <a class="medical medical_review" href="/d/html/5972.html" rel="external">"Candida infections in children"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PERITONITIS AND INTRA-ABDOMINAL INFECTIONS</span></p><p class="headingAnchor" id="H1607773899"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span><em>Candida</em> species frequently contribute to polymicrobial infections that occur following surgery on the gastrointestinal (GI) tract; upper GI tract surgery is more likely to lead to intra-abdominal candidiasis than lower GI tract surgery [<a href="#rid1">1,2</a>]. Gut perforation, anastomotic leaks, and acute necrotizing pancreatitis are associated with intra-abdominal candidiasis [<a href="#rid3">3-10</a>]. A multicenter study performed from January 2015 to December 2016 that included 26 European intensive care units (ICU) found that recurrent gastrointestinal perforation, anastomotic leakage, presence of an abdominal drain, and prior receipt of antifungal drugs or antibiotics were independently associated with the development of intra-abdominal candidiasis [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H1385288005"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>Intra-abdominal manifestations of <em>Candida</em> infection include discrete abscesses from a GI tract, biliary, or pancreatic source, secondary peritonitis from a GI tract, biliary, or pancreatic source, infected necrotic pancreas, gangrenous cholecystitis, and obstruction to the common bile duct with a <em>Candida</em> fungus ball [<a href="#rid7">7,12-14</a>]. Patients with intra-abdominal candidiasis may have candidemia, but the majority do not have blood cultures yielding <em>Candida</em> and present a more difficult diagnostic problem [<a href="#rid15">15</a>]. <em>C. albicans</em> is the predominant species isolated in intra-abdominal candidal infections, but <em>Candida glabrata</em> has assumed an increasing role at some centers [<a href="#rid16">16,17</a>].</p><p>The symptoms of <em>Candida</em> peritonitis do not differ from those of bacterial peritonitis, and in as many as two-thirds of patients, both bacteria and <em>Candida</em> are found as the cause of peritonitis [<a href="#rid14">14</a>]. Fevers, chills, and abdominal pain are prominent symptoms. Septic shock is commonly noted and in various studies is reported between 18 percent and 55 percent [<a href="#rid14">14,17,18</a>].</p><p>A retrospective review of 163 patients with intra-abdominal candidiasis between 2012 and 2013 at a single center noted that 55 percent had abscesses and 33 percent had secondary peritonitis that originated with a gastrointestinal source [<a href="#rid14">14</a>]. The remaining patients had pancreatitis with necrosis, cholecystitis, cholangitis, and primary peritonitis. Only 6 percent had candidemia. Source control within five days and antifungal therapy within five days were each implemented in 72 percent of patients. Overall mortality was 28 percent, but mortality among those who had primary or secondary peritonitis was 88 and 40 percent, respectively. Abscesses, early source control, and young age were independent predictors of decreased mortality.</p><p>A similar study retrospectively assessed outcomes for 82 patients who had intra-abdominal candidiasis, of which 61 percent had peritonitis, 23 percent had abscesses, and 16 percent had biliary tract infections. More than half (55 percent) of the patients had septic shock at the time intra-abdominal candidiasis was diagnosed. Appropriate source control (HR=0.08 [0.02-0.3], p&lt;.001), appropriate antifungal therapy (HR=0.14 [0.04-0.55], p&lt;.005), and a combination of both factors (HR=0.02 [0.0-0.08], p&lt;.001]) were associated with improved 30-day survival [<a href="#rid18">18</a>]. </p><p class="headingAnchor" id="H3689307879"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis is best made by aspiration of fluid under computed tomographic (CT) or ultrasound guidance or at the time of surgery. Growth of <em>Candida</em> species from an abscess or peritoneal fluid should lead to the diagnosis of invasive intra-abdominal candidiasis and to appropriate treatment with an antifungal agent. Culture of <em>Candida </em>species from an indwelling drain is not adequate for the diagnosis of infection because it often reflects only colonization of the drain.</p><p>Blood cultures frequently show no growth in patients with intra-abdominal candidiasis [<a href="#rid19">19</a>]. In several large studies of patients with intra-abdominal candidiasis, only 6 to 20 percent had positive blood cultures [<a href="#rid14">14,17,18</a>].</p><p>The serum beta-D-glucan (BDG) assay appears to be a useful test in patients with intra-abdominal candidiasis [<a href="#rid15">15</a>]. BDG is present in the cell wall of many fungi, including <em>Candida</em> spp and is also present in some medications and other products that are used in the hospital setting. Because of this, a positive BDG test result cannot be used for the diagnosis of a specific fungal infection but rather can be viewed as a marker for a possible fungal infection that should be sought by more specific testing. In a prospective cohort study that included 89 patients who had been in the intensive care unit for ≥72 hours and who were considered to be at high risk for intra-abdominal candidiasis because of recurrent gastrointestinal tract perforation or acute necrotizing pancreatitis, 29 (33 percent) developed intra-abdominal candidiasis; 27 of 29 patients (93 percent) had negative blood cultures [<a href="#rid20">20</a>]. The sensitivity and specificity of two consecutive positive BDG results for predicting intra-abdominal candidiasis were 65 and 78 percent, respectively. BDG results became positive in patients with intra-abdominal candidiasis a median of five days before the diagnosis was confirmed by culture of intra-abdominal specimens [<a href="#rid20">20</a>].</p><p>Conversely, and more importantly, a negative BDG test in a patient at risk for intra-abdominal candidiasis is highly predictive of the absence of invasive candidiasis and can be used as a means by which antifungal therapy, which is often given empirically in an ICU setting, can be safely stopped [<a href="#rid19">19,21-23</a>]. Thus, obtaining a BDG test on admission to the intensive care unit in patients with intra-abdominal events, such as bowel perforation or necrotizing pancreatitis, may provide a clue as to whether intra-abdominal candidiasis is a possibility or seems unlikely. This assay does not supplant cultures, which are needed to identify which specific fungal species might be causing infection. The BDG assay is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/2462.html" rel="external">"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults", section on 'Beta-D-glucan assay'</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Treatment of intra-abdominal candidiasis usually entails both surgical intervention and antifungal therapy [<a href="#rid23">23,24</a>]. Surgical management involves drainage of abscesses and relief of biliary tract obstruction. Adequate source control was independently associated with improved survival in a retrospective study of intra-abdominal candidiasis [<a href="#rid14">14</a>]. Depending on the location of the abscess, drainage can often be performed by an interventional radiologist, obviating the need for a laparotomy. Initial antifungal therapy is similar to that for candidemia [<a href="#rid23">23</a>].</p><p>The preferred initial treatment is an echinocandin (<a class="drug drug_general" data-topicid="10141" href="/d/drug information/10141.html" rel="external">micafungin</a> 100 mg intravenously [IV] daily; <a class="drug drug_general" data-topicid="8744" href="/d/drug information/8744.html" rel="external">anidulafungin</a> 200 mg loading dose, then 100 mg IV daily; or <a class="drug drug_general" data-topicid="9175" href="/d/drug information/9175.html" rel="external">caspofungin</a> 70 mg loading dose, then 50 mg IV daily) (<a class="graphic graphic_table graphicRef87676" href="/d/graphic/87676.html" rel="external">table 1</a>). <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">Fluconazole</a> (800 mg [12 mg/kg] loading dose, then 400 mg [6 mg/kg] orally daily) is an alternative that can be used in patients who are not critically ill, who have not been treated recently with fluconazole, and who are not considered likely to have a fluconazole-resistant isolate (eg, not colonized with a fluconazole-resistant species, such as <em>C. glabrata</em>)<em> </em>[<a href="#rid23">23</a>]<em>.</em> A lipid formulation of amphotericin B (3 to 5 mg/kg IV daily) is another alternative, but it is used infrequently because of the greater toxicity (particularly nephrotoxicity) of this agent.</p><p>Following identification of the infecting species, treatment can be modified as follows, provided that the patient is clinically stable:</p><p class="bulletIndent1"><span class="glyph">●</span>For fluconazole-susceptible species, such as <em>C. albicans</em>, <em>Candida parapsilosis</em>, and <em>Candida tropicalis</em>, <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> (800 mg [12 mg/kg] loading dose, then 400 mg [6 mg/kg] orally daily) can be used. The concentrations of fluconazole achieved in bile are as high or higher than the levels achieved in serum [<a href="#rid13">13</a>], and excellent concentrations are achieved in peritoneal fluid. (See  <a class="medical medical_review" href="/d/html/495.html" rel="external">"Pharmacology of azoles"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When <em>C. glabrata</em> is the cause of infection, the preferred initial agent is an echinocandin. <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">Voriconazole</a> has also been approved for the treatment of <em>Candida</em> intra-abdominal infections and can be used for oral step-down therapy after initial intravenous echinocandin therapy once the patient has shown improvement and the source of the infection is adequately controlled. However, susceptibilities should be obtained before using voriconazole for fluconazole-resistant <em>C. glabrata</em> isolates because of the high probability of cross-resistance with <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>. (See  <a class="medical medical_review" href="/d/html/2430.html" rel="external">"Management of candidemia and invasive candidiasis in adults"</a>.)</p><p></p><p>Therapy should continue for at least two weeks and often longer, until the abscess and signs and symptoms of peritonitis are resolved.</p><p class="headingAnchor" id="H4"><span class="h1">PNEUMONIA</span><span class="headingEndMark"> — </span>Primary pneumonia due to <em>Candida</em> species is extremely rare. The pathogenesis of lung involvement is that of hematogenous spread rather than aspiration of oropharyngeal secretions. Thus, multiple microabscesses are found scattered widely throughout the lung parenchyma, and lobar infiltrates are uncommon. Autopsy studies from cancer centers have documented that primary <em>Candida</em> pneumonia, in which infection is limited to the lungs, occurs in less than 1 percent of cases [<a href="#rid25">25,26</a>]. Much more commonly, the lungs are one of many organs involved in the course of disseminated infection with <em>Candida</em> in immunosuppressed patients [<a href="#rid23">23,25</a>]. In a review of a 20-year experience from the MD Anderson Cancer Center, there were only 31 cases of clearly documented primary <em>Candida</em> pneumonia in over 7000 autopsies in cancer patients [<a href="#rid25">25</a>].</p><p>In one study of 17 hematopoietic cell transplant recipients who had histologically proven pulmonary candidiasis, the computed tomographic (CT) findings included multiple nodules ranging from 3 to 30 mm in diameter in 15 patients, air-space consolidation in 11 patients, and nodules surrounded by discrete areas of ground-glass opacity (CT halo sign) in five patients [<a href="#rid27">27</a>].</p><p>Studies in both cancer patients and nonneutropenic patients in an intensive care unit (ICU) setting have confirmed the lack of specificity of sputum or bronchoalveolar lavage (BAL) specimens for the diagnosis of pulmonary invasion by <em>Candida</em> [<a href="#rid26">26,28-30</a>]. Among 36 cancer patients with autopsy evidence of <em>Candida</em> pneumonia in whom sputum and/or BAL were performed ≤4 weeks before death, the sensitivity and specificity was found to be 85 and 60 percent for sputum culture and 71 and 57 percent for BAL [<a href="#rid26">26</a>].</p><p>In a prospective study of 232 ICU patients who died with pneumonia and underwent autopsy, none of 77 patients with <em>Candida</em> spp isolated from a tracheal aspirate or BAL fluid had histopathologic evidence of <em>Candida</em> pneumonia [<a href="#rid31">31</a>]. Similarly, in a study of 1077 BAL specimens obtained from 555 mechanically ventilated patients in an intensive care unit, only 8 percent yielded <em>Candida</em> species [<a href="#rid30">30</a>]. Of these 85 samples, 92 percent were judged to reflect colonization only. Only two patients were treated for presumed <em>Candida</em> pneumonia.</p><p class="headingAnchor" id="H5"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Treatment is not recommended for <em>Candida</em> isolated from sputum or BAL specimens [<a href="#rid23">23</a>]. Patients with disseminated candidiasis who develop secondary <em>Candida</em> pneumonia should be treated for disseminated disease. (See  <a class="medical medical_review" href="/d/html/2430.html" rel="external">"Management of candidemia and invasive candidiasis in adults"</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">EMPYEMA</span><span class="headingEndMark"> — </span>In four series of patients with <em>Candida</em> empyema, the most common pathogen was <em>C. albicans, </em>followed by either<em> C. glabrata </em>or <em>C. tropicalis </em>[<a href="#rid32">32-35</a>]. In one series including 81 patients, bacterial pathogens were isolated along with <em>Candida</em> in half of the patients, and more than one bacterial species was isolated in nearly one-third of cases [<a href="#rid32">32</a>]. Most patients were severely ill in the intensive care unit and many had antecedent surgery or an invasive procedure on the thorax or abdomen prior to development of <em>Candida</em> empyema. Spontaneous rupture of the esophagus was noted in several reports and carried a poor prognosis [<a href="#rid32">32,35</a>]. </p><p>Most patients were managed with an antifungal agent and closed drainage [<a href="#rid32">32-35</a>]; in one study, video-assisted thorascopic surgery or open thoracotomy were also performed [<a href="#rid32">32</a>]. The overall mortality rate for the two reports that focused on <em>Candida</em> empyema ranged from 27 to 62 percent [<a href="#rid32">32,34</a>]; it is uncertain whether a more aggressive drainage approach contributed to lower mortality. </p><p class="headingAnchor" id="H7"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Empiric treatment of <em>Candida</em> empyema consists of either an echinocandin or an azole. Targeted treatment should be guided by microbiologic identification, species-based risk for azole resistance, and antifungal susceptibility test results. </p><p>Data on the concentration of antifungal agents in empyema fluid are limited [<a href="#rid36">36</a>]. Most data are from case reports that provide values for one antifungal agent in a single patient. One series that included 81 patients noted an association between increased mortality and use of an echinocandin rather than <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> (odds ratio 4.5, 95% CI 1.1-18.8), raising questions regarding echinocandin penetration and activity in the pleural space [<a href="#rid32">32</a>]. However, limitations of this study were the retrospective design and that only one agent (<a class="drug drug_general" data-topicid="9175" href="/d/drug information/9175.html" rel="external">caspofungin</a>) was evaluated; it is possible that illness severity may have led clinicians to select an echinocandin over fluconazole [<a href="#rid32">32</a>]. </p><p>The duration of antifungal therapy should be guided by individual circumstances. A minimum of two weeks of antifungal therapy following decortication or chest tube removal may be sufficient; in some circumstances, a longer duration may be needed.</p><p class="headingAnchor" id="H8"><span class="h1">MEDIASTINITIS</span><span class="headingEndMark"> — </span><em>Candida </em>mediastinitis almost always occurs as a complication of thoracic surgical procedures [<a href="#rid37">37-40</a>]. In a report of nine cases of <em>Candida</em> mediastinitis, the primary clinical manifestations included chest wall erythema and/or drainage, fever, and sternal instability [<a href="#rid37">37</a>]. These findings are similar to those seen with bacterial causes of postoperative mediastinitis. (See  <a class="medical medical_review" href="/d/html/7014.html" rel="external">"Postoperative mediastinitis after cardiac surgery"</a>.)</p><p>All patients had received prior antibiotic therapy, and the median time from surgery to disease onset was 11 days (range 6 to 100 days) [<a href="#rid37">37</a>]. The course was complicated in seven patients by contiguous or hematogenous spread. The diagnosis was delayed in three patients because intraoperative cultures were not obtained or cultures positive for <em>Candida</em> were considered contaminants.</p><p>In this study and an earlier review of 39 published cases of <em>Candida</em> mediastinitis, mortality was 55 percent [<a href="#rid37">37,39</a>]. In the latter report, no patient who had not undergone a mediastinal drainage procedure survived compared with survival in 11 of 13 patients (85 percent) who underwent mediastinal drainage [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Mediastinal drainage with debridement of affected bone in combination with antifungal therapy is essential for cure. The choice of agent should be similar to that recommended for candidemia. Thus, an echinocandin (<a class="drug drug_general" data-topicid="10141" href="/d/drug information/10141.html" rel="external">micafungin</a> 100 mg intravenously [IV] daily; <a class="drug drug_general" data-topicid="8744" href="/d/drug information/8744.html" rel="external">anidulafungin</a> 200 mg loading dose, then 100 mg IV daily; or <a class="drug drug_general" data-topicid="9175" href="/d/drug information/9175.html" rel="external">caspofungin</a> 70 mg loading dose, then 50 mg IV daily) is recommended (<a class="graphic graphic_table graphicRef87676" href="/d/graphic/87676.html" rel="external">table 1</a>). <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">Fluconazole</a> (800 mg [12 mg/kg] loading dose, then 400 mg [6 mg/kg] daily) can be used for susceptible species. A lipid formulation of amphotericin B (3 to 5 mg/kg IV daily) is an alternative. Therapy is prolonged in most cases and only stopped when all clinical and laboratory signs of infection have resolved.</p><p>In many cases, sternal osteomyelitis accompanies mediastinal infection, which requires prolonged therapy with oral <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> for susceptible species. For patients who have <em>C. glabrata</em> mediastinitis and perhaps osteomyelitis, <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> is the most appropriate agent for long-term oral therapy provided that the isolate is susceptible. It is important to note that susceptibilities should be obtained before using voriconazole for fluconazole-resistant <em>C. glabrata</em> isolates because of the high probability of cross-resistance with fluconazole (see  <a class="medical medical_review" href="/d/html/2430.html" rel="external">"Management of candidemia and invasive candidiasis in adults"</a>). If sternal involvement is present, the duration of therapy may extend to six months or longer. Clinical response, improvement in inflammatory markers (erythrocyte sedimentation rate, C-reactive protein), and resolution of computed tomographic scan findings are the usual parameters that help determine length of oral therapy.</p><p class="headingAnchor" id="H10"><span class="h1">PERICARDITIS</span><span class="headingEndMark"> — </span>Purulent pericarditis due to <em>Candida</em> species is rare but life threatening. It most often arises as a complication of previous thoracic surgery or contiguous spread from an adjacent focus, but hematogenous spread can occur [<a href="#rid41">41-43</a>]. <em>C. albicans</em> is the most common pathogen, but infection with <em>C. tropicalis</em> and <em>C. glabrata</em> have been described [<a href="#rid42">42-44</a>].</p><p>In a literature review of 25 cases, 21 had either undergone thoracic surgery or had disseminated candidiasis [<a href="#rid42">42</a>]. Immunocompromise and antibiotic therapy are risk factors, as they are for almost all <em>Candida</em> infections [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/d/html/2416.html" rel="external">"Overview of Candida infections", section on 'Risk factors for invasive infection'</a>.)</p><p>The clinical presentation may be subtle and nonspecific in some patients [<a href="#rid41">41</a>], but other patients will present with an enlarging cardiac shadow on chest radiography and/or signs of cardiac tamponade. The diagnosis is confirmed by a positive culture of pericardial fluid or finding yeast forms on pericardial biopsy.</p><p class="headingAnchor" id="H11"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Untreated <em>Candida</em> pericarditis is almost uniformly fatal [<a href="#rid41">41,42</a>]. Tamponade must be treated emergently with decompression and subsequently with a pericardial window or pericardiectomy to prevent recurrent hemodynamic compromise [<a href="#rid23">23,41-44</a>]. Although not recommended, occasional patients have survived with only pericardiocentesis and antifungal therapy [<a href="#rid42">42,45</a>]. (See  <a class="medical medical_review" href="/d/html/4921.html" rel="external">"Cardiac tamponade"</a>.)</p><p>Therapy with an echinocandin (<a class="drug drug_general" data-topicid="10141" href="/d/drug information/10141.html" rel="external">micafungin</a> 100 mg intravenously [IV] daily; <a class="drug drug_general" data-topicid="8744" href="/d/drug information/8744.html" rel="external">anidulafungin</a> 200 mg loading dose, then 100 mg IV daily; or <a class="drug drug_general" data-topicid="9175" href="/d/drug information/9175.html" rel="external">caspofungin</a> 70 mg loading dose, then 50 mg IV daily) is recommended (<a class="graphic graphic_table graphicRef87681" href="/d/graphic/87681.html" rel="external">table 2</a>) [<a href="#rid23">23</a>]. If the organism is <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> susceptible, fluconazole (800 mg [12 mg/kg] loading dose, then 400 [6 mg/kg] orally daily) can be used. A lipid formulation of amphotericin B (3 to 5 mg/kg IV daily) is an alternative. Patients receiving an echinocandin can be switched to oral fluconazole (400 to 800 mg [6 to 12 mg/kg] daily) if the organism is susceptible when they are clinically stable.</p><p>For pericarditis due to <em>C. glabrata</em>, echinocandin therapy followed by oral <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> (400 mg orally twice daily for two doses, then 200 mg twice daily) is an option. However, susceptibilities should be obtained before using voriconazole for fluconazole-resistant <em>C. glabrata</em> isolates because of the high probability of cross-resistance with <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>. (See  <a class="medical medical_review" href="/d/html/2430.html" rel="external">"Management of candidemia and invasive candidiasis in adults"</a>.)</p><p>The optimal length of therapy is not known. The patient should be followed clinically and therapy stopped only when there are no signs of ongoing pericardial inflammation and all systemic signs of infection, such as an elevated erythrocyte sedimentation rate and anemia, have resolved.</p><p class="headingAnchor" id="H2573686652"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/104270.html" rel="external">"Society guideline links: Candidiasis"</a>.)</p><p class="headingAnchor" id="H25389396"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intra-abdominal infections</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Sources</strong> – <em>Candida</em> species frequently contribute to polymicrobial intra-abdominal infections. Sources include gut perforation, anastomotic leaks after bowel surgery, acute necrotizing pancreatitis, peritoneal dialysis infection, gangrenous cholecystitis, and common bile duct fungus balls. Discrete abscesses with or without peritonitis can occur. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Microbiology</strong> – <em>Candida albicans</em> is the predominant species isolated in intra-abdominal candidal infections, but <em>Candida glabrata</em> has assumed an increasing role at some centers. (See <a class="local">'Peritonitis and intra-abdominal infections'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diagnosis</strong> – Growth of <em>Candida</em> species from an abscess or peritoneal fluid should lead to the diagnosis of invasive intra-abdominal candidiasis and to appropriate treatment with an antifungal agent. Culture of <em>Candida</em> species from an indwelling drain is not adequate for the diagnosis of infection. The serum beta-D-glucan (BDG) assay can be a useful adjunct to cultures of an abscess or peritoneal fluid and may become positive before the diagnosis is established by culture. (See <a class="local">'Peritonitis and intra-abdominal infections'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment</strong> – Treatment usually entails both surgical intervention and antifungal therapy. The choice of agent depends upon the <em>Candida </em>species. Surgical management involves drainage of abscesses and relief of biliary tract obstruction. An echinocandin is recommended, but <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> is an alternative for fluconazole-susceptible isolates (<a class="graphic graphic_table graphicRef87676" href="/d/graphic/87676.html" rel="external">table 1</a>). A lipid formulation of amphotericin B is another alternative, but it is used infrequently because of the greater toxicity of this agent. (See <a class="local">'Treatment'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infections of the thorax</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pneumonia</strong> – Primary pneumonia due to <em>Candida</em> species is extremely rare. The pathogenesis of lung involvement is that of hematogenous spread rather than aspiration of oropharyngeal secretions. Thus, multiple microabscesses are found scattered widely throughout the lung parenchyma, and lobar infiltrates are uncommon. Treatment is not recommended for <em>Candida</em> isolated from sputum or bronchoalveolar lavage specimens. Patients with disseminated candidiasis who develop secondary <em>Candida</em> pneumonia should be treated for disseminated disease. (See <a class="local">'Pneumonia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Empyema</strong> – Empiric treatment of <em>Candida</em> empyema consists of either an echinocandin or an azole. Targeted treatment should be guided by microbiologic identification, species-based risk for azole resistance, and antifungal susceptibility test results. (See <a class="local">'Empyema'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mediastinitis</strong> – <em>Candida</em> mediastinitis almost always occurs as a complication of thoracic surgical procedures. Mediastinal drainage with debridement of affected bone in combination with antifungal therapy is essential for cure. The choice of agent should be similar to that recommended for candidemia. An echinocandin is the preferred initial agent. <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">Fluconazole</a> is an alternative if the isolate is susceptible. A lipid formulation of amphotericin B is a less frequently used alternative. Therapy is prolonged in most cases and only stopped when all clinical and laboratory signs of infection have resolved. (See <a class="local">'Mediastinitis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pericarditis</strong> – Purulent pericarditis due to <em>Candida</em> species is rare but life threatening. It most often arises as a complication of previous thoracic surgery or contiguous spread from an adjacent focus, but hematogenous spread can occur. An echinocandin is the preferred initial agent. <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">Fluconazole</a> is an alternative for fluconazole-susceptible isolates. A lipid formulation of amphotericin B is another alternative. (See <a class="local">'Pericarditis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antifungal regimens</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Echinocandins – <a class="drug drug_general" data-topicid="10141" href="/d/drug information/10141.html" rel="external">Micafungin</a> 100 mg intravenously (IV) daily; <a class="drug drug_general" data-topicid="8744" href="/d/drug information/8744.html" rel="external">anidulafungin</a> 200 mg loading dose, then 100 mg IV daily; or <a class="drug drug_general" data-topicid="9175" href="/d/drug information/9175.html" rel="external">caspofungin</a> 70 mg loading dose, then 50 mg IV daily</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A lipid formulation of amphotericin B – 3 to 5 mg/kg IV daily</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">Fluconazole</a> – 800 mg (12 mg/kg) loading dose, then 400 mg (6 mg/kg) orally daily\</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Carneiro HA, Mavrakis A, Mylonakis E. Candida peritonitis: an update on the latest research and treatments. World J Surg 2011; 35:2650.</a></li><li><a class="nounderline abstract_t">Brotfain E, Sebbag G, Friger M, et al. Invasive Candida Infection after Upper Gastrointestinal Tract Surgery for Gastric Cancer. Int J Surg Oncol 2017; 2017:6058567.</a></li><li><a class="nounderline abstract_t">Calandra T, Bille J, Schneider R, et al. Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet 1989; 2:1437.</a></li><li><a class="nounderline abstract_t">Sandven P, Qvist H, Skovlund E, et al. Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations. Crit Care Med 2002; 30:541.</a></li><li><a class="nounderline abstract_t">Grewe M, Tsiotos GG, Luque de-Leon E, Sarr MG. Fungal infection in acute necrotizing pancreatitis. J Am Coll Surg 1999; 188:408.</a></li><li><a class="nounderline abstract_t">Hoerauf A, Hammer S, Müller-Myhsok B, Rupprecht H. Intra-abdominal Candida infection during acute necrotizing pancreatitis has a high prevalence and is associated with increased mortality. Crit Care Med 1998; 26:2010.</a></li><li><a class="nounderline abstract_t">Keiser P, Keay S. Candidal pancreatic abscesses: report of two cases and review. Clin Infect Dis 1992; 14:884.</a></li><li><a class="nounderline abstract_t">Vege SS, Gardner TB, Chari ST, et al. Outcomes of intra-abdominal fungal vs. bacterial infections in severe acute pancreatitis. Am J Gastroenterol 2009; 104:2065.</a></li><li><a class="nounderline abstract_t">de Ruiter J, Weel J, Manusama E, et al. The epidemiology of intra-abdominal flora in critically ill patients with secondary and tertiary abdominal sepsis. Infection 2009; 37:522.</a></li><li><a class="nounderline abstract_t">Montravers P, Lepape A, Dubreuil L, et al. Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study. J Antimicrob Chemother 2009; 63:785.</a></li><li><a class="nounderline abstract_t">Bassetti M, Vena A, Giacobbe DR, et al. Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study. Infect Dis Ther 2022; 11:827.</a></li><li><a class="nounderline abstract_t">Morris AB, Sands ML, Shiraki M, et al. Gallbladder and biliary tract candidiasis: nine cases and review. Rev Infect Dis 1990; 12:483.</a></li><li><a class="nounderline abstract_t">Bozzette SA, Gordon RL, Yen A, et al. Biliary concentrations of fluconazole in a patient with candidal cholecystitis: case report. Clin Infect Dis 1992; 15:701.</a></li><li><a class="nounderline abstract_t">Vergidis P, Clancy CJ, Shields RK, et al. Intra-Abdominal Candidiasis: The Importance of Early Source Control and Antifungal Treatment. PLoS One 2016; 11:e0153247.</a></li><li><a class="nounderline abstract_t">Clancy CJ, Nguyen MH. Finding the "missing 50%" of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis 2013; 56:1284.</a></li><li><a class="nounderline abstract_t">Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20:133.</a></li><li><a class="nounderline abstract_t">Bassetti M, Righi E, Ansaldi F, et al. A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Med 2015; 41:1601.</a></li><li><a class="nounderline abstract_t">Yan T, Li SL, Ou HL, et al. Appropriate Source Control and Antifungal Therapy are Associated with Improved Survival in Critically Ill Surgical Patients with Intra-abdominal Candidiasis. World J Surg 2020; 44:1459.</a></li><li><a class="nounderline abstract_t">Clancy CJ, Nguyen MH. Non-Culture Diagnostics for Invasive Candidiasis: Promise and Unintended Consequences. J Fungi (Basel) 2018; 4.</a></li><li><a class="nounderline abstract_t">Tissot F, Lamoth F, Hauser PM, et al. β-glucan antigenemia anticipates diagnosis of blood culture-negative intraabdominal candidiasis. Am J Respir Crit Care Med 2013; 188:1100.</a></li><li><a class="nounderline abstract_t">Posteraro B, De Pascale G, Tumbarello M, et al. Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1→3)-β-D-glucan assay, Candida score, and colonization index. Crit Care 2011; 15:R249.</a></li><li><a class="nounderline abstract_t">Hanson KE, Pfeiffer CD, Lease ED, et al. β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study. PLoS One 2012; 7:e42282.</a></li><li><a class="nounderline abstract_t">Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.</a></li><li><a class="nounderline abstract_t">Bassetti M, Marchetti M, Chakrabarti A, et al. A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Med 2013; 39:2092.</a></li><li><a class="nounderline abstract_t">Haron E, Vartivarian S, Anaissie E, et al. Primary Candida pneumonia. Experience at a large cancer center and review of the literature. Medicine (Baltimore) 1993; 72:137.</a></li><li><a class="nounderline abstract_t">Kontoyiannis DP, Reddy BT, Torres HA, et al. Pulmonary candidiasis in patients with cancer: an autopsy study. Clin Infect Dis 2002; 34:400.</a></li><li><a class="nounderline abstract_t">Franquet T, Müller NL, Lee KS, et al. Pulmonary candidiasis after hematopoietic stem cell transplantation: thin-section CT findings. Radiology 2005; 236:332.</a></li><li><a class="nounderline abstract_t">Rello J, Esandi ME, Díaz E, et al. The role of Candida sp isolated from bronchoscopic samples in nonneutropenic patients. Chest 1998; 114:146.</a></li><li><a class="nounderline abstract_t">el-Ebiary M, Torres A, Fàbregas N, et al. Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients. An immediate postmortem histologic study. Am J Respir Crit Care Med 1997; 156:583.</a></li><li><a class="nounderline abstract_t">Wood GC, Mueller EW, Croce MA, et al. Candida sp. isolated from bronchoalveolar lavage: clinical significance in critically ill trauma patients. Intensive Care Med 2006; 32:599.</a></li><li><a class="nounderline abstract_t">Meersseman W, Lagrou K, Spriet I, et al. Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study. Intensive Care Med 2009; 35:1526.</a></li><li><a class="nounderline abstract_t">Senger SS, Thompson GR 3rd, Samanta P, et al. Candida Empyema Thoracis at Two Academic Medical Centers: New Insights Into Treatment and Outcomes. Open Forum Infect Dis 2021; 8:ofaa656.</a></li><li><a class="nounderline abstract_t">Nigo M, Vial MR, Munita JM, et al. Fungal empyema thoracis in cancer patients. J Infect 2016; 72:615.</a></li><li><a class="nounderline abstract_t">Lin KH, Liu YM, Lin PC, et al. Report of a 63-case series of Candida empyema thoracis: 9-year experience of two medical centers in central Taiwan. J Microbiol Immunol Infect 2014; 47:36.</a></li><li><a class="nounderline abstract_t">Ko SC, Chen KY, Hsueh PR, et al. Fungal empyema thoracis: an emerging clinical entity. Chest 2000; 117:1672.</a></li><li><a class="nounderline abstract_t">Felton T, Troke PF, Hope WW. Tissue penetration of antifungal agents. Clin Microbiol Rev 2014; 27:68.</a></li><li><a class="nounderline abstract_t">Clancy CJ, Nguyen MH, Morris AJ. Candidal mediastinitis: an emerging clinical entity. Clin Infect Dis 1997; 25:608.</a></li><li><a class="nounderline abstract_t">Malani PN, McNeil SA, Bradley SF, Kauffman CA. Candida albicans sternal wound infections: a chronic and recurrent complication of median sternotomy. Clin Infect Dis 2002; 35:1316.</a></li><li><a class="nounderline abstract_t">Glower DD, Douglas JM Jr, Gaynor JW, et al. Candida mediastinitis after a cardiac operation. Ann Thorac Surg 1990; 49:157.</a></li><li><a class="nounderline abstract_t">Pertowski CA, Baron RC, Lasker BA, et al. Nosocomial outbreak of Candida albicans sternal wound infections following cardiac surgery traced to a scrub nurse. J Infect Dis 1995; 172:817.</a></li><li><a class="nounderline abstract_t">Rabinovici R, Szewczyk D, Ovadia P, et al. Candida pericarditis: clinical profile and treatment. Ann Thorac Surg 1997; 63:1200.</a></li><li><a class="nounderline abstract_t">Schrank JH Jr, Dooley DP. Purulent pericarditis caused by Candida species: case report and review. Clin Infect Dis 1995; 21:182.</a></li><li><a class="nounderline abstract_t">Neughebauer B, Alvarez V, Harb T, Keefer M. Constrictive pericarditis caused by candida glabrata in an immunocompetent patient: case report and review of literature. Scand J Infect Dis 2002; 34:615.</a></li><li><a class="nounderline abstract_t">Chaudhary K, Faidas A, Baddour LM. Candida pericarditis: unusual complication following hiatal hernia repair. Infect Dis Clin Pract 1996; 5:339.</a></li><li><a class="nounderline abstract_t">Karp R, Meldahl R, McCabe R. Candida albicans purulent pericarditis treated successfully without surgical drainage. Chest 1992; 102:953.</a></li></ol></div><div id="topicVersionRevision">Topic 2436 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21976010" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Candida peritonitis: an update on the latest research and treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29234525" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Invasive Candida Infection after Upper Gastrointestinal Tract Surgery for Gastric Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2574368" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical significance of Candida isolated from peritoneum in surgical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11990912" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10195725" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Fungal infection in acute necrotizing pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9875913" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Intra-abdominal Candida infection during acute necrotizing pancreatitis has a high prevalence and is associated with increased mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1576283" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Candidal pancreatic abscesses: report of two cases and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19491825" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Outcomes of intra-abdominal fungal vs. bacterial infections in severe acute pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19669089" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The epidemiology of intra-abdominal flora in critically ill patients with secondary and tertiary abdominal sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19196742" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35182353" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2193353" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Gallbladder and biliary tract candidiasis: nine cases and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1420685" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Biliary concentrations of fluconazole in a patient with candidal cholecystitis: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27123857" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Intra-Abdominal Candidiasis: The Importance of Early Source Control and Antifungal Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23315320" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Finding the "missing 50%" of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17223626" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Epidemiology of invasive candidiasis: a persistent public health problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26077063" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31965275" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Appropriate Source Control and Antifungal Therapy are Associated with Improved Survival in Critically Ill Surgical Patients with Intra-abdominal Candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29463043" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Non-Culture Diagnostics for Invasive Candidiasis: Promise and Unintended Consequences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23782027" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : β-glucan antigenemia anticipates diagnosis of blood culture-negative intraabdominal candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22018278" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Early diagnosis of candidemia in intensive care unit patients with sepsis: a prospective comparison of (1→3)-β-D-glucan assay, Candida score, and colonization index.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22879929" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26679628" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24105327" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8502166" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Primary Candida pneumonia. Experience at a large cancer center and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11774088" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pulmonary candidiasis in patients with cancer: an autopsy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15955852" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pulmonary candidiasis after hematopoietic stem cell transplantation: thin-section CT findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9674461" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The role of Candida sp isolated from bronchoscopic samples in nonneutropenic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9279244" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients. An immediate postmortem histologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16477410" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Candida sp. isolated from bronchoalveolar lavage: clinical significance in critically ill trauma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19357832" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33889656" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Candida Empyema Thoracis at Two Academic Medical Centers: New Insights Into Treatment and Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26945845" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Fungal empyema thoracis in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23102708" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Report of a 63-case series of Candida empyema thoracis: 9-year experience of two medical centers in central Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10858401" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Fungal empyema thoracis: an emerging clinical entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24396137" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Tissue penetration of antifungal agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9314447" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Candidal mediastinitis: an emerging clinical entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12439793" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Candida albicans sternal wound infections: a chronic and recurrent complication of median sternotomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2404472" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Candida mediastinitis after a cardiac operation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7658076" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Nosocomial outbreak of Candida albicans sternal wound infections following cardiac surgery traced to a scrub nurse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9124944" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Candida pericarditis: clinical profile and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7578728" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Purulent pericarditis caused by Candida species: case report and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12238580" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Constrictive pericarditis caused by candida glabrata in an immunocompetent patient: case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Candida pericarditis: unusual complication following hiatal hernia repair</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1516431" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Candida albicans purulent pericarditis treated successfully without surgical drainage.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
